Vor Biopharma Working With Janssen Biotech on Leukemia Treatment
July 09 2021 - 7:28AM
Dow Jones News
By Chris Wack
Vor Biopharma Inc. said it formed a collaboration with Janssen
Biotech Inc., one of the Janssen Pharmaceutical Companies of
Johnson & Johnson, to develop engineered hematopoietic stem
cell transplants combined with a bi-specific antibody therapy for
acute myeloid leukemia.
Under the terms of the collaboration, Vor Biopharma will
investigate the combination of these technologies into a treatment
solution, pairing Vor's "invisible" eHSC transplant platform with
one of Janssen's bi-specific antibodies in development for acute
myeloid leukemia.
The collaboration agreement provides that each company retains
all rights and ownership to their respective programs and
platforms.
Vor Biopharma is a cell-therapy company founded by PureTech
Health PLC.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 09, 2021 07:27 ET (11:27 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Vor Biopharma (NASDAQ:VOR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Vor Biopharma (NASDAQ:VOR)
Historical Stock Chart
From Oct 2023 to Oct 2024
